Doma Biopharmaceutical is a biotechnology company focused on drug research and development. It utilizes proprietary platforms for the development of fully human monoclonal and bispecific antibodies. The company has integrated in vivo drug efficacy screening with robust clinical development expertise to enhance the efficiency of the drug development process. By streamlining these processes, Doma Biopharmaceutical aims to assist global partners in producing a diverse range of antibody-based therapeutics.
Adlai Nortye Biopharma Co., Ltd. is a biopharmaceutical company based in Hangzhou, China, focused on the research and development of innovative treatments for cancer and metabolic diseases. Founded in 2004 and formerly known as Sinopep Pharmaceutical Inc., the company has shifted its emphasis to oncology and immuno-oncology. Adlai Nortye is committed to improving patient outcomes through the discovery and commercialization of differentiated medicines. With a solid foundation in peptide and protein drug development, the company has broadened its scope to include small molecules and therapeutic antibodies. It holds 23 granted patents and has published 7 PCT applications. Through strategic collaborations with global partners, Adlai Nortye has established a diverse pipeline of programs ranging from early pre-clinical stages to those ready for phase 3 clinical trials.
Private Equity Round in 2021
CanSemi is a chip manufacturing plant that manufactures microprocessors, power management chips, analog chips, and power discrete devices.
EpimAb Biotherapeutics is a biopharmaceutical company based in Shanghai, China, focused on the research and development of novel bispecific antibody therapeutics. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, the company creates bispecific molecules that possess antibody-like properties. This innovative approach aims to address the challenges associated with developing effective bi-specific antibodies, which are engineered from two different monoclonal antibodies to combine their therapeutic features into a single entity. These bispecific antibodies hold promise for treating various life-threatening conditions, particularly in immuno-oncology, by offering new therapeutic options. Despite the potential benefits of bi-specific antibodies, many candidates face hurdles in development due to issues related to their binding properties, pharmacokinetics, and production costs. EpimAb Biotherapeutics is positioned to contribute to the growing need for advanced bi-specific therapeutics in the pharmaceutical industry.
Zhejiang Zero Run Technology Co., Ltd. (LEAPMOTOR) is an innovative intelligent electric vehicle enterprise jointly invested by Zhejiang Dahua Technology Co., Ltd. and its main founders. Founded in 2015, the company is headquartered in Hangzhou Binjiang High-tech Development Zone. The company's business scope covers intelligent electric vehicle design, R&D, intelligent driving, motor electronic control, battery system development, and cloud computing-based car networking solutions. Relying on the strong financial strength of Dahua and its mature experience in technology research and development, process system and quality management, the company emphasizes the culture of engineers and has the ultimate pursuit of technological innovation, industrial design, and process quality.
Zylox Medical Device Co. was founded in the beautiful city of Hangzhou in 2012 by a group of highly skillful and experienced returnees from the US and Europe. They have on average 5-20 years of working experiences in various functional areas such as research and development, management, and manufacturing in leading device makers including Johnson & Johnson, Medtronic, and Abbott before returning to China. Since its inception, Zylox has developed an increasingly rich product pipeline of interventional and implantable peripheral vascular devices such as PTA balloons, PTA drug-coated Balloons (PTA DCB), superficial femoral artery (SFA) stent, drug-eluting SFA stent, and other vascular accessories. Zylox strives to continuously innovate and provide patients with superior quality medical devices.
Beijing Mabworks Biotech Co., Ltd. is a biotechnology company based in Beijing, China, specializing in the research and development of gene-engineered antibody drugs. Founded in 2003, Mabworks focuses on the discovery, development, manufacturing, and commercialization of therapeutic antibodies. The company’s portfolio includes several products, such as MIL77, an Ebola treatment, MIL60, a biosimilar to the cancer drug Bevacizumab, and MIL62, which targets chronic lymphocytic leukemia. Additionally, Mabworks is involved in the development of innovative antibody drugs aimed at addressing various cancers and autoimmune diseases, leveraging advances in immunology and cancer biology.
Suzhou Ribo Life Science is a developer of RNA interference ( RNAi ) technology designed to treat liver diseases. The company's RNA interference ( RNAi ) technology is used to develop nucleic acid therapeutic drugs and related products, enabling healthcare providers to deliver more effective pharmaceuticals to patients.
Peijia Medical Limited specializes in the research, development, production, and sales of interventional medical devices aimed at treating structural heart and neurovascular diseases. Founded in 2012 and based in Suzhou, China, the company offers a range of transcatheter aortic valve replacement (TAVR) products, including its TaurusOne, TaurusElite, and TaurusNXT systems. Additionally, Peijia is advancing the development of transcatheter mitral and tricuspid valve replacement devices, as well as ancillary products such as lithotripsy and balloon aortic valvuloplasty catheters. The company also produces neurointerventional products, including stent retrievers and various catheter types designed for complex vascular procedures. With a focus on both transcatheter valve therapeutic and neurointerventional markets, Peijia Medical operates from a modern facility that combines advanced technology with an aesthetically pleasing design, reflecting its commitment to innovation in the medical device industry.
EpimAb Biotherapeutics is a biopharmaceutical company based in Shanghai, China, focused on the research and development of novel bispecific antibody therapeutics. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, the company creates bispecific molecules that possess antibody-like properties. This innovative approach aims to address the challenges associated with developing effective bi-specific antibodies, which are engineered from two different monoclonal antibodies to combine their therapeutic features into a single entity. These bispecific antibodies hold promise for treating various life-threatening conditions, particularly in immuno-oncology, by offering new therapeutic options. Despite the potential benefits of bi-specific antibodies, many candidates face hurdles in development due to issues related to their binding properties, pharmacokinetics, and production costs. EpimAb Biotherapeutics is positioned to contribute to the growing need for advanced bi-specific therapeutics in the pharmaceutical industry.
Qingtuanshe, founded in 2013, is a university part-time employment and flexible platform that is committed to more users. Qingtuanshe offers safer, richer, and more efficient part-time services to professional part-time recruitment services for more companies. As of January 2019, the registered users of Qingtuanshe is 6 million+, the number of registered companies is 100,000+, and the number of part-time applicants per day reached 240,000.
Zylox Medical Device Co. was founded in the beautiful city of Hangzhou in 2012 by a group of highly skillful and experienced returnees from the US and Europe. They have on average 5-20 years of working experiences in various functional areas such as research and development, management, and manufacturing in leading device makers including Johnson & Johnson, Medtronic, and Abbott before returning to China. Since its inception, Zylox has developed an increasingly rich product pipeline of interventional and implantable peripheral vascular devices such as PTA balloons, PTA drug-coated Balloons (PTA DCB), superficial femoral artery (SFA) stent, drug-eluting SFA stent, and other vascular accessories. Zylox strives to continuously innovate and provide patients with superior quality medical devices.
FitSAMO is an orthopaedic surgical equipment supplier.
Banma Zhixing is a global platform focused on vehicle solutions, primarily for the automotive and transportation sectors. The company specializes in developing smart car operating systems and comprehensive digital transportation solutions. By offering its AliOS in-car operating system to developers and car manufacturers, Banma Zhixing aims to enhance the functionality and connectivity of vehicles. Through its innovative approaches, the company seeks to fulfill the potential of connected cars and improve the overall travel experience for consumers.
TSC Laser Technology Development (Beijing) Co., Ltd. provides 3D printing services. The firm is headquartered in China.
RootCloud is a cloud computing platform based in Beijing, China, that focuses on industrial applications and the internet of things (IoT). Founded in 2016, it provides a comprehensive suite of services for machine manufacturers, equipment users, government agencies, and other organizations. The platform facilitates online management of industrial assets through a multi-layered architecture that includes connection, platform, and application layers. It offers solutions in areas such as smart manufacturing, research and development, energy management, and industrial artificial intelligence. RootCloud specializes in delivering IoT and big data services, enabling large-scale manufacturing enterprises to achieve digital transformation and improve operational efficiency. Through its service-as-a-service model hosted on the public cloud, RootCloud supports clients in enhancing product quality and reinforcing core competencies.
LP Pharmaceuticals (Xiamen) Co., Ltd., located in Xiamen Biomedical Industry Base which formulates and manufactures pharmaceuticals with enhanced delivery properties. The company was founded in 2012 by a group of scientists and business professionals with extensive experience in the US and Chinese pharmaceutical industry. Proprietary delivery platforms include mucosal and oral controlled release. Therapeutic areas currently concern central nervous system, digestive system, cardiovascular, cancer and AIDS.
TSC Laser Technology Development (Beijing) Co., Ltd. provides 3D printing services. The firm is headquartered in China.
Zensun (Shanghai) Sci & Tech Co., Ltd. is a biopharmaceutical company focusing on the development of innovative ‘first in class’ bio-therapeutic products for the treatment of serious and life-threatening unmet medical needs. They discover new medicines using novel disease specific targets and innovative technologies. The patented discoveries are then developed into therapies. With adherence to the tenet of “healing for life”, we hope to transform the lives of heart failure and cancer patients by providing them with drugs that treat their disease and not the symptoms. Zensun’s current pipeline covers cardiovascular disease treatment, anti-cancer drugs, and treatments for energy metabolism disorders.
Ninebot Inc. is a Beijing-based company that specializes in the design, development, manufacturing, distribution, and sale of short-distance personal transportation products. Founded in 2012 by Gao Lufeng, Ninebot focuses on eco-friendly, electric, and self-balancing vehicles aimed at enhancing short-range commuting. The company operates through a network of distributors and retail points, serving customers both in China and internationally.
United Imaging Healthcare develops and manufactures a wide range of medical equipment and solutions, focusing on diagnostic imaging, radiotherapy, and healthcare information technology. The company's product offerings include advanced imaging devices such as computed tomography, molecular imaging, magnetic resonance systems, and digital radiography solutions. Notable products include the uCT 510, uMI 510 PET-CT scanner, and uMR 560 imaging device. Additionally, United Imaging provides the uCloud UIH Intelligent Medical Cloud platform for resource sharing and data analysis. The company also offers comprehensive customer support, technical assistance, and training services. Established in 2011 and headquartered in Shanghai, China, United Imaging Healthcare has expanded its operations to various locations, including the United States, with facilities in cities like Concord, Cleveland, and Houston. The company has strategic partnerships to enhance its offerings and reach in the healthcare sector.
CF PharmTech, Inc. develops and manufactures inhalation products. The company’s products include metered dose inhaler (MDI), dry powder inhalers (DPI), nasal sprays, nebulizer, and respiratory medicines. It provides contract manufacturing organization (CMO) services. It conducts research and development in the areas of asthma, chronic obstructive pulmonary disease (COPD), and rhinitis. The company was founded in 2007 and is based in Suzhou, China.
CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.
Maxwell Technologies specializes in the development, manufacturing, and marketing of energy storage and power delivery solutions across various sectors, including automotive, heavy transportation, renewable energy, backup power, wireless communications, and industrial and consumer electronics. The company also produces radiation-hardened microelectronic components and systems for satellites and spacecraft. Its product offerings include ultra-high voltage capacitors, truck starting capacitors, and generator starting capacitors, all designed to deliver cost-effective, energy-efficient, and environmentally friendly performance. Maxwell Technologies focuses on ensuring reliable, failure-free operation for the most demanding applications throughout their lifecycle.
Suzhou Ribo Life Science is a developer of RNA interference ( RNAi ) technology designed to treat liver diseases. The company's RNA interference ( RNAi ) technology is used to develop nucleic acid therapeutic drugs and related products, enabling healthcare providers to deliver more effective pharmaceuticals to patients.
Novogene Co., Ltd. is a global leader in genomic services and solutions, specializing in next-generation sequencing (NGS) and bioinformatics. Established in 2011 and headquartered in Beijing, the company offers a wide range of genomic services, including human genome sequencing, cancer genomic profiling, and microbial genome sequencing, among others. Novogene also provides clinical-grade sequencing services and innovative diagnostic tools such as NovoFocus, designed for PARP inhibitor therapies, and NovoNeoantigen, which identifies cancer neoantigens from paired tumor-normal samples. With a workforce of approximately 1,800 employees and multiple global locations, Novogene boasts the largest sequencing capacity worldwide. The company has made significant contributions to the field, holding 49 NGS-related patents and facilitating the publication of over 1,850 research papers in prestigious journals. Founder Dr. Ruiqiang Li, a prominent figure in genomics, has been instrumental in advancing the company's capabilities and expertise, emphasizing the integration of sequencing and informatics to accelerate scientific progress for its clients.
Developer of database software in China. The company provides database software solutions to enterprises in finance, telecommunications, government, energy, transportation, and national defense industries, enabling businesses to use domestic-developed software.